Investor Alert

London Markets Open in:

Market Pulse Archives

Aug. 11, 2020, 6:02 p.m. EDT

Moderna stock pops after agreement to sell at least 100 million COVID-19 vaccine doses to U.S. government

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jeremy C. Owens

Moderna Inc. /zigman2/quotes/205619834/composite MRNA +12.20% announced Tuesday afternoon that it has reached an agreement to sell 100 million doses of its investigational vaccine for COVID-19 to the U.S. government for more than $1.5 billion. "Breaking: Moderna announces a supply agreement with the U.S. government to secure an initial 100 million doses of mRNA-1273 for up to $1.525 billion with option granted to U.S. government to purchase up to an additional 400 million doses," the company revealed in a tweet . Moderna shares jumped more than 8% in after-hours trading immediately following the announcement. Earlier studies of Moderna's vaccine candidate produced antibodies for COVID-19, the company previously announced, and it is currently operating a Phase 3 study of the vaccine. "The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself," Moderna added in a subsequent news release . "As is customary with government-purchased vaccines, healthcare professionals could charge for the cost of administering the vaccine." Moderna shares have exploded higher amid the frenzy to develop a COVID-19 vaccine during a worldwide pandemic, with the share price jumping more than 250% so far this year as the S&P 500 index /zigman2/quotes/210599714/realtime SPX +0.36% has gained 5.2%.

US : U.S.: Nasdaq
$ 147.00
+15.98 +12.20%
Volume: 26.97M
Jan. 25, 2021 4:15p
P/E Ratio
Dividend Yield
Market Cap
$51.85 billion
Rev. per Employee
+13.89 +0.36%
Volume: 2.79B
Jan. 25, 2021 5:15p

Get news alerts on Moderna Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.